Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Keyser

Vascular Surgery Lewisburg, PA Doctor of Osteopathy

NPI 1568773232 CMS profile 778272

3 Hospital Dr Ste 100, Lewisburg, PA 17837

Open in the dashboard

General payments

$2,672

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Keyser of Lewisburg, PA is reported in the CMS Open Payments database as having received $2,672 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $106 3
2023 General $224 6
2022 General $464 16
2021 General $938 11
2020 General $732 14
2019 General $208 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Keyser
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Benjamin Keyser were reported at $106. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Benjamin Keyser Vascular Surgery median Middle half National median
2019 $208 $796 $226–$2,363 $163
2020 $732 $348 $118–$1,110 $114
2021 $938 $471 $158–$1,421 $132
2022 $464 $725 $222–$2,183 $149
2023 $224 $836 $257–$2,440 $160
2024 $0 $909 $252–$2,619 $164
2025 $106 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $945 11 payments
  2. Bard Peripheral Vascular, Inc. $740 16 payments
  3. Janssen Pharmaceuticals, Inc $314 15 payments
  4. Boston Scientific Corporation $144 3 payments
  5. Abbott Laboratories $105 1 payment
  6. Bayer HealthCare Pharmaceuticals Inc. $99 1 payment
  7. Pfizer Inc. $71 6 payments
  8. Penumbra, Inc. $43 1 payment
  9. Philips Electronics North America Corporation $41 2 payments
  10. Becton, Dickinson and Company $35 1 payment
  11. Other $137 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,689 59 payments
  2. Travel and Lodging $982 5 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Neuroprotection System $945 11 payments
  2. ENROUTE Transcarotid Stent $945 11 payments
  3. ENHANCE Transcarotid Peripheral Access Kit $713 7 payments
  4. ENROUTE .014 Guidewire $713 7 payments
  5. XARELTO $314 15 payments
  6. GENERAL - METALLIC STENTS $120 1 payment
  7. JOT DX $105 1 payment
  8. Kerendia $99 1 payment
  9. LUTONIX $81 1 payment
  10. ELIQUIS $71 6 payments
  11. Other $454 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

419

Median for Vascular Surgery: 122

Drug cost

$39,235

Median for Vascular Surgery: $14,135

Branded share of claims

73.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 23 $15,593
Xarelto Rivaroxaban Brand 27 $12,090
Brilinta Ticagrelor Brand 12 $5,890
Clopidogrel Clopidogrel Bisulfate Brand 213 $3,048
Cilostazol Generic 77 $1,957
Atorvastatin Calcium Generic 23 $344
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 16 $179
Metronidazole Generic 12 $90
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$80,244

Medicare's payments for the services billed

Medicare patients

811

Average age 76

Services billed

1,732

413 women, 398 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 43%
Diabetes 40%
Chronic kidney disease 32%
Heart failure 27%
Depression 24%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record